Vasoprotective Effects of Prolonged Therapy With Perindopril A in Patients with Hypertension Including Concomitant Type 2 Diabetes Mellitus

Objective Investigate the dynamics of morphological and functional markers of vascular remodeling in patients with arterial hypertension (AH), including those with concomitant type 2 diabetes mellitus (DM2), during 12-month administration of perindopril A.
Material and Methods The study included patients with grade I-II AH, with and without DM2 (30 and 32 patients, respectively), who underwent outpatient correction of initially ineffective antihypertensive therapy and administration of perindopril A, 10 mg/day. Morphological and functional parameters of vascular remodeling were evaluated in all patients at baseline and at 12 months using photoplethysmography. Stiffness index (SI) and phase shift (PS) were measured in large vessels. Reflection index (RI) and occlusion index (OI) were measured in microvessels. Computed nailfold videocapillaroscopy was used to determine capillary density (CD) at rest (CDr), CD during venous occlusion test (CDvo), and CD during reactive hyperemia test (CDrh). Data are medians [interquartile range].
Results After 12-month administration of perindopril A, the morphological and functional parameters of vascular remodeling in AH patients without DM2 significantly improved at all vascular levels. SI decreased to 9.25 [7.8; 10.93 ] m/s and PS increased to 7.4 [5.6; 9.05] ms. In microvasculature, a statistically significant reduction was observed in RI, 31 [27; 36.5]%, and an increase was observed in OI, which characterizes endothelium function, 1.75 [1.68; 1.9]. Capillary CDr significantly increased to 40.5 [34.93; 46] cap/mm2, as did CDvo and CDrh. At the same time, in the group of patients with AH and DM2, a significant improvement was observed for the large vessels. SI decreased to 9.8 [9.08; 10.58] m/s, and PS increased to 6.95 [5.13; 10.08]. The RI index, reflecting the structural condition of arterioles, significantly decreased to 34 [25.9; 45.53]%, and the OI index, characterizing endothelial function, did not change significantly, 1.4 [1.3; 1.6]. Capillary CDr significantly increased to 31.55 [27.68; 34.7 ] cap/mm2; however, CDvo and CDrh did not change significantly. Renal function improved in both groups.
Conclusion Both groups demonstrated improvement of morphological parameters at all levels of the arterial bed. However, patients with AH and concomitant DM2 showed no improvement of the endothelial function of arterioles and capillaries compared to improvement in AH patients without DM2. This reflected the more severe endothelial dysfunction present in AH patients with DM2.

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. The Lancet. 2005;365(9455):217–23. DOI: 10.1016/S0140-6736(05)17741-1

2. Tarasenko N.A. Diabetes: reality, forecasts, prevention. Modern problems of science and education. 2017;6:34. [Russian]

3. Kozakova M, Palombo C. Diabetes Mellitus, ArterialWall, and Cardiovascular Risk Assessment. International Journal of Environmental Research and Public Health. 2016;13(2):201. DOI: 10.3390/ijerph13020201

4. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal. 2013;34(28):2159–219. DOI: 10.1093/eurheartj/eht151

5. Castorena-Gonzalez JA, Staiculescu MC, Foote C, Martinez-Lemus LA. Mechanisms of the Inward Remodeling Process in Resistance Vessels: Is the Actin Cytoskeleton Involved? Microcirculation. 2014;21(3):219–29. DOI: 10.1111/micc.12105

6. Yasmin, Wallace S, McEniery CM, Dakham Z, Pusalkar P, Maki-Petaja K et al. Matrix Metalloproteinase-9 (MMP-9), MMP-2, and Serum Elastase Activity Are Associated With Systolic Hypertension and Arterial Stiffness. Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25(2):372–8. DOI: 10.1161/01.ATV.0000151373.33830.41

7. Tan J, Hua Q, Xing X, Wen J, Liu R, Yang Z. Impact of the Metalloproteinase-9/Tissue Inhibitor of Metalloproteinase-1 System on Large Arterial Stiffness in Patients with Essential Hypertension. Hypertension Research. 2007;30(10):959–63. DOI: 10.1291/hypres.30.959

8. Niemirska A, Litwin M, Trojanek J, Gackowska L, Kubiszewska I, Wierzbicka A et al. Altered matrix metalloproteinase 9 and tissue inhibitor of metalloproteinases 1 levels in children with primary hypertension. Journal of Hypertension. 2016;34(9):1815–22. DOI: 10.1097/HJH.0000000000001024

9. Weigert C, Brodbeck K, Klopfer K, Häring H, Schleicher E. Angiotensin II induces human TGF-β1 promoter activation: similarity to hyperglycaemia. Diabetologia. 2002;45(6):890–8. DOI: 10.1007/s00125-002-0843-4

10. Pohlers D, Brenmoehl J, Löffler I, Müller CK, Leipner C, Schultze-Mosgau S et al. TGF-β and fibrosis in different organs – molecular pathway imprints. Biochimica et Biophysica Acta (BBA) Molecular Basis of Disease. 2009;1792(8):746–56. DOI: 10.1016/j.bbadis.2009.06.004

11. Harvey A, Montezano AC, Lopes RA, Rios F, Touyz RM. Vascular Fibrosis in Aging and Hypertension: Molecular Mechanisms and Clinical Implications. Canadian Journal of Cardiology. 2016;32(5):659–68. DOI: 10.1016/j.cjca.2016.02.070

12. Fels J, Jeggle P, Liashkovich I, Peters W, Oberleithner H. Nanomechanics of vascular endothelium. Cell and Tissue Research. 2014;355(3):727–37. DOI: 10.1007/s00441-014-1853-5

13. Adeva-Andany MM, Ameneiros-Rodríguez E, Fernández-Fernández C, Domínguez-Montero A, Funcasta-Calderón R. Insulin resistance is associated with subclinical vascular disease in humans. World Journal of Diabetes. 2019;10(2):63–77. DOI: 10.4239/wjd.v10.i2.63

14. Cardoso C, Salles G. Aortic Stiffness as a Surrogate Endpoint to Microand Macrovascular Complications in Patients with Type 2 Diabetes. International Journal of Molecular Sciences. 2016;17(12):2044. DOI: 10.3390/ijms17122044

15. Shah AS, Urbina EM. Vascular and Endothelial Function in Youth with Type 2 Diabetes Mellitus. Current Diabetes Reports. 2017;17(6):36. DOI: 10.1007/s11892-017-0869-0

16. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. New England Journal of Medicine. 2000;342(3):145–53. DOI: 10.1056/NEJM200001203420301

17. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. The Lancet. 2001;358(9287):1033–41. DOI: 10.1016/S0140-6736(01)06178-5

18. rugts JJ, Boersma E, Chonchol M, Deckers JW, Bertrand M, Remme WJ et al. The Cardioprotective Effects of the Angiotensin-Converting Enzyme Inhibitor Perindopril in Patients With Stable Coronary Artery Disease Are Not Modified by Mild to Moderate Renal Insufficiency. Journal of the American College of Cardiology. 2007;50(22):2148–55. DOI: 10.1016/j.jacc.2007.08.029

19. van Vark LC, Bertrand M, Akkerhuis KM, Brugts JJ, Fox K, Mourad J-J et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of reninangiotensin-aldosterone system inhibitors involving 158 998 patients. European Heart Journal. 2012;33(16):2088–97. DOI: 10.1093/eurheartj/ehs075

20. Patel A. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. The Lancet. 2007;370(9590):829–40. DOI: 10.1016/S0140-6736(07)61303-8

21. Belin de Chantemèle EJ, Vessières E, Guihot A-L, Toutain B, Maquignau M, Loufrani L et al. Type 2 diabetes severely impairs structural and functional adaptation of rat resistance arteries to chronic changes in blood flow. Cardiovascular Research. 2009;81(4):788–96. DOI: 10.1093/cvr/cvn334

22. Mulvany MJ. Small artery remodelling in hypertension: causes, consequences and therapeutic implications. Medical & Biological Engineering & Computing. 2008;46(5):461–7. DOI: 10.1007/s11517-008-0305-3

23. Sonoyama K, Greenstein A, Price A, Khavandi K, Heagerty T. Review: Vascular remodeling: implications for small artery function and target organ damage. Therapeutic Advances in Cardiovascular Disease. 2007;1(2):129–37. DOI: 10.1177/1753944707086358